Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region

References

• Hebnes JB, Olesen TB, Duun-Henriksen AK, Munk C, Norrild B, Kjaer SK. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med. 2014 Nov. 11(11):2630–6. doi:10.1111/jsm.12652.
   PubMed Web of Science ®Google Scholar
• Newman P, Lacombe-Duncan A. Human papillomavirus vaccination for men: advancing policy and practice. Future Virol. 2014;9(12):1033–47. doi:10.2217/fvl.14.91.
   Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 31;24(Suppl 3):S3/11–25. doi:10.1016/j.vaccine.2006.05.111.
   PubMed Web of Science ®Google Scholar
• de Sanjosé S, Serrano B, Tous S, de Sanjosé S, Alejo M, Lloveras B, Quirós B, Clavero O, Vidal A, Ferrándiz-Pulido C, et al. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2018;2(4). doi:10.1093/jncics/pky045.
   PubMedGoogle Scholar
• Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, Xu Y, Qian C. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Front Cell Infect Microbiol. 2022;12:12. 2022-July-04. doi:10.3389/fcimb.2022.909223.
   Web of Science ®Google Scholar
• Brisson M, Benard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily M-C, Smith MA, Berkhof J, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016 Nov;1(1):8–17. doi:10.1016/S2468-2667(16)30001-9.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard É, Perez N, Brisson M , Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D, et al. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Aug 10;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3.
   PubMed Web of Science ®Google Scholar
• de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020 Feb;8(2):180–90. doi:10.1016/S2214-109X(19)30488-7.
   PubMed Web of Science ®Google Scholar
• Lieblong BJ, Montgomery BEE, Su LJ, Nakagawa M. Natural history of human papillomavirus and vaccinations in men: a literature review. Health Sci Rep. 2019;2(5):e118. doi:10.1002/hsr2.118.
   PubMedGoogle Scholar
• Brotherton JML, Giuliano AR, Markowitz LE, Dunne EF, Ogilvie GS. Monitoring the impact of HPV vaccine in males—considerations and challenges. Papilloma Res. 2016 Dec;2:106–11. doi:10.1016/j.pvr.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Kmietowicz Z. Boys in England to get HPV vaccine from next year. BMJ. 2018 Jul 24;362:k3237. doi:10.1136/bmj.k3237.
   PubMedGoogle Scholar
• Parellada C, Perez Carrega M, Carvalho A, Massoc MA, Prieto E, Monsanto H, Cashat-Cruz M. Evolution of gender-neutral HPV vaccination in national immunization calendars in Latin America and the Caribbean, abstract Fri-Station 01.3. Int J Infect Dis. 2018;73(Suppl):82. doi:10.1016/j.ijid.2018.04.3612.
   Google Scholar
• Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Röbl-Mathieu M, Terhardt M, van der Sande M, Wichmann O, Zepp F, Klug SJ. Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2018;61(9):1170–86. 2018/09/01. doi:10.1007/s00103-018-2791-2.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Weekly Epidemiological Record [Online]. [Accessed 2019 Apr 4]. https://www.who.int/wer/2017/wer9219/en/.
   Google Scholar
• Parkin DM, Louie KS, Clifford G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine. 2008 Aug 19;26(Suppl 12):1–16. doi:10.1016/j.vaccine.2008.05.010.
   PubMedGoogle Scholar
• Family Health Service DoH. Schedule of Hong Kong childhood immunisation programme. [Accessed 2022 Jul]. https://www.fhs.gov.hk/english/main_ser/child_health/child_health_recommend.html.
   Google Scholar
• The Government of the Hong Kong Special Administrative Region. SFH chairs seventeenth meeting of cancer coordinating committee. [Accessed 2022 Jul]. https://www.info.gov.hk/gia/general/202206/07/P2022060700797.htm?fontSize=1.
   Google Scholar
• Ministry of Health Republic of Indonesia. Ministry of health adds 3 types of routine immunization vaccines, one of them is HPV. 2020. https://www.kemkes.go.id/article/view/22042400001/kemenkes-tambah-3-jenis-vaksin-imunisasi-rutin-salah-satunya-hpv.html.
   Google Scholar
• Ministry of Health Indonesia. Post-introduction evaluation of hpv vaccine programme in indonesia. [Accessed 2018 Nov 19]. https://www.who.int/docs/default-source/searo/indonesia/hpv-evaluation-vaccine-programme-post-introduction-final-report-nov2018.pdf?sfvrsn=9b63f1e9_2.
   Google Scholar
• Ministry of Health Labour and Welfare. Human papillomavirus infection-cervical cancer (cervical cancer) and HPV vaccine. [Accessed 2022 Jul]. https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/index.html.
   Google Scholar
• Center for Strategic & International Studies. HPV vaccination in Japan: the continuing debate and global impacts. [Accessed 2022 Aug 8]. https://www.csis.org/analysis/hpv-vaccination-japan-0.
   Google Scholar
• Buang SN, Ja’afar S, Pathmanathan I, Saint V. Human papillomavirus immunisation of adolescent girls: improving coverage through multisectoral collaboration in Malaysia. BMJ. 2018;363:k4602. doi:10.1136/bmj.k4602.
   PubMedGoogle Scholar
• Immunise 4 Life. The Malaysian National Immunisation Programme (NIP). [Accessed 2022 Jul]. https://immunise4life.my/the-malaysian-national-immunisation-programme-nip/.
   Google Scholar
• Bruni LAG, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human papillomavirus and related diseases in philippines. Barcelona, Spain: ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). 2021.
   Google Scholar
• Department of Health (DOH). 2013. Department memorandum no. 2013-0291: Guidelines in the implementation of human papillomavirus (HPV) vaccination in selected schools; 2013 August [accessed 2021 October 22]. https://doh.gov.ph/sites/default/files/publications/DOHGuidelinesSchoolbasedHPVvaccination.pdf.
   Google Scholar
• Phua LC, Choi HCW, Wu J, Jit M, Low J, Ng K, Pearce F, Hall C, Abdul Aziz MI. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine. 2021;39(16):2255–63. doi:10.1016/j.vaccine.2021.03.040.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Singapore. National childhood immunisation schedule. [Accessed 2022 Jul]. https://www.moh.gov.sg/resources-statistics/nationally-recommended-vaccines.
   Google Scholar
• Ministry of Health Singapore. MOH establishes national adult immunisation schedule; extends use of Medisave for vaccines under the schedule. [Accessed 2022 Jul]. https://www.moh.gov.sg/news-highlights/details/moh-establishes-national-adult-immunisation-schedule-extends-use-of-medisave-for-vaccines-under-the-schedule.
   Google Scholar
• Vijaya K, Goei AHY. Improved population coverage of the human papillomavirus vaccine after implementation of a school-based vaccination programme: the Singapore experience. Singapore Med J. 2023;64(5):294–301. doi:10.11622/smedj.2022053.
   Web of Science ®Google Scholar
• Ministry of Health Singapore. Changes to the national childhood immunisation schedule. [Accessed 2022 Aug 17]. https://www.cfps.org.sg/assets/1-Circular-for-GPs/4-MOH-Cir-No-180-2020-13Jul20-Updates-to-NCIS-doctors-1.pdf.
   Google Scholar
• Ministry of Health Singapore. Updates to the national adult immunisation schedule. [Accessed 2022 Aug 17]. https://www.primarycarepages.sg/GPRepository/Circular%20Documents/MOH%20Cir%20No%20182_2020_13Jul20_Updates%20to%20NAIS_doctors.pdf.
   Google Scholar
• Garland S. A significant measure of HPV vaccine effectiveness in a high-risk population in Korea prior to a national immunization program. J Gynecol Oncol. 2020;31(1):32. doi:10.3802/jgo.2020.31.e32.
   Web of Science ®Google Scholar
• Korean Disease Control and Prevention Agency. National immunization program for children. [Accessed 2022 Jul]. https://www.kdca.go.kr/contents.es?mid=a30333000000.
   Google Scholar
• World Health Organization. HPV vaccine included in national immunization programme. [Accessed 2022 Jul]. https://app.powerbi.com/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9.
   Google Scholar
• Korean Disease Control and Prevention Agency. HPV national vaccination support project. [Accessed 2022 Aug 17]. https://nip.kdca.go.kr/irgd/introduce.do?MnLv1=3&MnLv2=6.
   Google Scholar
• Health Promotion Administration Taiwan. QA: know HPV. [Accessed 2022 Jul]. https://www.hpa.gov.tw/Pages/List.aspx?nodeid=1799.
   Google Scholar
• Lee CC, Chen TS, Wu TZ, Huang LM. A human papillomavirus public vaccination program in Taiwan: the Kinmen County experience. J Formos Med Assoc. 2012 Dec;111(12):682–5. doi:10.1016/j.jfma.2012.10.004.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero, G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. Human Papillomavirus and Related Diseases in Thailand. Summary Rep. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). 2023 Mar 10.
   Google Scholar
• World Health Organization. Vaccination schedule for Thailand. [Accessed 2022 Jul]. https://immunizationdata.who.int/pages/schedule-by-country/tha.html?DISEASECODE=&TARGETPOP_GENERAL=.
   Google Scholar
• Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Deebukkham P, Kulkarni AS, Pavelyev A. The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand. PLOS ONE. 2021;16(2):e0245894. doi:10.1371/journal.pone.0245894.
   PubMed Web of Science ®Google Scholar
• Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F, Vaccarella S, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):197–206. doi:10.1016/S2214-109X(22)00501-0.
   PubMed Web of Science ®Google Scholar
• Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–92. doi:10.1016/S0140-6736(21)02178-4.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. JNCI J Nat Cancer Inst. 2021;113(10):1329–35. doi:10.1093/jnci/djab080.
   PubMedGoogle Scholar
• Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–8. 2020/10/01. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• Khoo SP, Muhammad Ridzuan Tan NA, Rajasuriar R, Nasir NH, Gravitt P, Ng CW, Woo YL. Changes in genital human papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program. PLOS One. 2022;17(12):e0278477. doi:10.1371/journal.pone.0278477.
   PubMed Web of Science ®Google Scholar
• Haruyama R, Obara H, Fujita N. Japan resumes active recommendations of HPV vaccine after 8.5 years of suspension. Lancet Oncol. 2022;23(2):197–8. doi:10.1016/S1470-2045(22)00002-X.
   PubMed Web of Science ®Google Scholar
• Sekine M, Yamaguchi M, Kudo R, Hanley SJB, Ueda Y, Adachi S, Kurosawa M, Miyagi E, Hara M, Enomoto T, et al. Suspension of proactive recommendations for HPV vaccination has led to a significant increase in HPV infection rates in young Japanese women: real-world data. Lancet Reg Health West Pac. 2021 Nov. 16:100300. doi:10.1016/j.lanwpc.2021.100300.
   PubMedGoogle Scholar
• Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Publ Health. 2020 Apr. 5(4):223–34. doi:10.1016/s2468-2667(20)30010-4.
   PubMed Web of Science ®Google Scholar
• Yagi A, Ueda Y, Nakagawa S, Ikeda S, Tanaka Y, Sekine M, Miyagi E, Enomoto T, Kimura T. Potential for cervical cancer incidence and death resulting from Japan’s current policy of prolonged suspension of its governmental recommendation of the HPV vaccine. Sci Rep. 2020 Sep 29. 10(1):15945. doi:10.1038/s41598-020-73106-z.
   PubMed Web of Science ®Google Scholar
• Yagi A, Ueda Y, Nakagawa S, Ikeda S, Kakuda M, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Mizushima T, et al. Can catch-up vaccinations fill the void left by suspension of the governmental recommendation of HPV vaccine in Japan? Vaccines. 2022 Sep 2;10(9):1455. doi:10.3390/vaccines10091455.
   Web of Science ®Google Scholar
• Tsu VD, LaMontagne DS, Atuhebwe P, Bloem PN, Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects. Prevent Med. 2021 Mar;144:106335. doi:10.1016/j.ypmed.2020.106335.
   PubMed Web of Science ®Google Scholar
• Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, Moreira ED, Baraldi E, Jessen H, Ferenczy A, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22(3):413–25. doi:10.1016/S1473-3099(21)00327-3.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85. doi:10.1056/NEJMoa1010971.
   PubMed Web of Science ®Google Scholar
• Tsentemeidou A, Fyrmpas G, Stavrakas M, Vlachtsis K, Sotiriou E, Poutoglidis A, Tsetsos N. Human papillomavirus vaccine to end oropharyngeal cancer. A systematic review and meta-analysis. Sex Transm Dis. 2021;48(9):700–7. doi:10.1097/OLQ.0000000000001405.
   PubMed Web of Science ®Google Scholar
• Wang L, Liang Y, Zhang X, Yang J. Vaccine attitudes among young adults in Asia: a systematic review. Hum Vaccines Immunother. 2021;17(4):1142–55. 2021/04/03. doi:10.1080/21645515.2020.1810486.
   PubMed Web of Science ®Google Scholar
• World Health Organization. COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades. 2022 Dec 15. https://www.who.int/news/item/15-07-2022-covid-19pandemic-fuels-largest-continued-backslide-in-vaccinations-in-three-decades.
   Google Scholar
• Elfström KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis. 2016;213(2):199–205. doi:10.1093/infdis/jiv368.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. https://www.who.int/publications/i/item/9789240014107.
   Google Scholar
• Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily M-C, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–90. doi:10.1016/S0140-6736(20)30068-4.
   PubMed Web of Science ®Google Scholar